Deniz Can Güven

1. Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancerSahin T. K., Orhan C., Ozercan I. H., Muglu H., Er B., Akyildiz A., et al.Experimental Hematology and Oncology, cilt.15, sa.1, 2026 (SCI-Expanded, Scopus)
2. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancerCengiz M., BOZKURT O., NURANSOY CENGİZ A., İNANÇ M., ÖZKAN M., Mutlu Ozkan E., et al.Discover Oncology, cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)
3. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumabAğdaş G., Bayir D., Şahin E., Cengiz M., GÜVEN D. C., Demir M. S., et al.Scientific Reports, cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)
4. Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumabKÖLEMEN E., UYGUN K., ÇABUK D., ERMAN M., Kılıçkap S., KÖŞECİ T., et al.Discover Oncology, cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)
5. Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patientsCengiz M., BOZKURT O., Cengiz A. N., GÜVEN D. C., Sahin E., Ozkan E. M., et al.Scientific Reports, cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)
6. Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancerBernstein-Molho R., Sella T., Delucchi V., Coussy F., Kim H. J., Linn S., et al.European Journal of Cancer, cilt.245, 2026 (SCI-Expanded, Scopus)
7. Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective StudyTaban H., AKSOY S., GÜVEN D. C., AKTAŞ B. Y., Yılmaz F., Aslan F., et al.Medicina (Lithuania), cilt.62, sa.9, 2026 (SCI-Expanded, Scopus)
8. Safety evaluation of TOPAZ-1 and KEYNOTE-966 regimens in metastatic biliary tract cancer: a systematic review and meta-analysisVitale E., Maistrello L., Ciccimarra F., GÜVEN D. C., ŞAHİN T. K., Monteiro F. S. M., et al.Clinical and Experimental Metastasis, cilt.43, sa.4, 2026 (SCI-Expanded, Scopus)
9. Demographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from TurkeyDişli A. K., Durukan B. M., Aşık E., NURANSOY CENGİZ A., Emin G., Yıldırım H. Ç., et al.Medicina (Lithuania), cilt.62, sa.8, 2026 (SCI-Expanded, Scopus)
10. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology GroupTunbekici S., Bal H., Kınıkoglu O., Arvas H., Muglu H., BİLİCİ A., et al.Clinical and Translational Oncology, cilt.28, sa.8, ss.3160-3169, 2026 (SCI-Expanded, Scopus)
11. Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory BiomarkersŞahin G., Dişli A. K., ŞİRVAN F., Mıdık M. M., Boyraz N. E., Belen O., et al.Medicina (Lithuania), cilt.62, sa.7, 2026 (SCI-Expanded, Scopus)
12. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeyyar M., Kalem A., SALİ M., Karabuğa B., ŞAHİN T. K., Dişli A. K., et al.Current Oncology, cilt.33, sa.6, 2026 (SCI-Expanded, Scopus)
13. Digital health technology in oncology: results from a survey by the ESMO Young Oncologists Committee and medical student alumniMandó P., Moutafi M., Connolly E., Faulkner L., Franco P., GÜVEN D. C., et al.ESMO Real World Data and Digital Oncology, cilt.12, 2026 (ESCI, Scopus)
14. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint InhibitorsŞahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.Journal of Oncological Science, cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin)
15. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology GroupTunbekici S., Sahin G., Ön S., Oruc A., Eryılmaz M. K., SAKİN A., et al.International Journal of Cancer, cilt.158, sa.7, ss.1881-1890, 2026 (SCI-Expanded, Scopus)
16. Immunotherapy in locally advanced head and neck squamous cell carcinoma: The current status and future outlookKöylü B., Selçukbiricik F., AKSOY S., GÜVEN D. C.Critical Reviews in Oncology/Hematology, cilt.219, 2026 (SCI-Expanded, Scopus)
17. Prediction models for overall survival and all-cause mortality risk in older adults with cancer: a systematic reviewDuquenne P., Liposits G., Vonnes C. O., Navarrete E., Serrano A. G., Canoui-Poitrine F., et al.The Lancet Healthy Longevity, cilt.7, sa.3, 2026 (SCI-Expanded, Scopus)
18. Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)On S., Cebeci S., Turna Z. H., Güç Sevgen Z. G., GÜVEN D. C., Kılıçkap S., et al.Cancers, cilt.18, sa.3, 2026 (SCI-Expanded, Scopus)
19. Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort StudyKarahan L., Akyildiz A., Sahin T. K., Batu M. A., ERŞAN Y. Ç., ONUR M. R., et al.Journal of Clinical Medicine, cilt.15, sa.4, 2026 (SCI-Expanded, Scopus)
20. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective AnalysisKÖKSAL B., Yildirim H. C., GÜVEN D. C., Kose F., Koymen G., Ozdemir O., et al.Journal of Clinical Medicine, cilt.15, sa.4, 2026 (SCI-Expanded, Scopus)
21. Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Studyİcli M. C., GÜVEN D. C., Akyildiz A., Gürbüz A. F., Majidova N., Kıdı M. M., et al.Journal of Clinical Medicine, cilt.15, sa.4, 2026 (SCI-Expanded, Scopus)
22. Cell therapy in sarcoma: Current landscape and future directionsSahin T. K., Germetaki T., GÜVEN D. C., AKIN S., DİZDAR Ö., Thistlethwaite F., et al.Journal for ImmunoTherapy of Cancer, cilt.14, sa.1, 2026 (SCI-Expanded, Scopus)
23. Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective StudyÇakır E., Divriklioğlu D., GÜVEN D. C., Özel G. S., Yıldız O., Emin G., et al.International Journal of Cancer, 2026 (SCI-Expanded, Scopus)
24. Artificial intelligence in cancer screening: a narrative review of current evidence and future directionsYazarkan Y., Sonmez G., Sahin T. K., Rizzo A., GÜVEN D. C.Expert Review of Molecular Diagnostics, cilt.26, sa.2, ss.149-172, 2026 (SCI-Expanded, Scopus)
25. Enhancing early prediction of pathological complete response in breast cancer using attention-based convolutional neural networks in digital pathologyComes M. C., Lupo A., Bozzi A., Fanizzi A., Cirillo A., Nunzio G. D., et al.Digital Health, cilt.12, 2026 (SCI-Expanded, SSCI, Scopus)
26. Harnessing the power of artificial intelligence for clinical trials in cancerSonmez G., Yazarkan Y., Sahin T. K., GÜVEN D. C.Expert Review of Anticancer Therapy, cilt.26, sa.6, ss.735-749, 2026 (SCI-Expanded, Scopus)
27. Asthenia in cancer patients receiving immune checkpoint Inhibitors (ICIs): the MOUSEION-11 systematic review and meta-analysisVitale E., Soares A., Rizzo A., Maistrello L., Cauli O., Brunetti O., et al.Clinical and Translational Oncology, 2026 (SCI-Expanded, Scopus)
28. Consolidative thoracic radiotherapy following first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: A systematic review and meta-analysisCanaslan K., Kahraman E. G., ÖZTOP İ., GÜVEN D. C.Therapeutic Advances in Medical Oncology, cilt.18, 2026 (SCI-Expanded, Scopus)
29. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung CancerNURANSOY CENGİZ A., BOZKURT O., Cengiz M., ÖZKAN M., İNANÇ M., KEFELİ U., et al.Journal of Clinical Medicine, cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)
30. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumabGüren A. K., DEMİRCAN N. C., GÜMÜŞAY Ö., Şimşek E. T., Kemik F., KARAOĞLU Ç., et al.Immunotherapy, cilt.18, sa.4, ss.317-326, 2026 (SCI-Expanded, Scopus)
31. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studySahin T. K., Kemik F., Muglu H., Acikgöz Yildiz B., Biter S., Tunbekici S., et al.Therapeutic Advances in Medical Oncology, cilt.18, 2026 (SCI-Expanded, Scopus)
32. Elacestrant in metastatic breast cancer: current advancements and future perspectivesSahin T. K., Makasheva B., GÜVEN D. C., AKSOY S., Di Lauro V., Rizzo A.Expert Review of Anticancer Therapy, cilt.26, sa.6, ss.697-706, 2026 (SCI-Expanded, Scopus)
33. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancerYILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.Acta Medica, cilt.56, sa.3, ss.186-198, 2025 (TRDizin)
34. Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemikahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.Turkish Journal of Clinics and Laboratory, cilt.16, sa.2, ss.255-262, 2025 (TRDizin)
35. Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping reviewGÜVEN D. C., Thong M. S., Arndt V.Journal of Cancer Survivorship, cilt.19, sa.3, ss.806-845, 2025 (SCI-Expanded, SSCI, Scopus)
36. Early Changes in Volumetric Body Composition Parameters Predict Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted TherapyAKTEPE O. H., ERDEMİR A. G., Yildirim E. C., Demirciler E., ULAŞLI T., GÜVEN D. C., et al.JOURNAL OF CLINICAL MEDICINE, cilt.14, sa.9, 2025 (SCI-Expanded, Scopus)
37. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)Majidova N., YASLIKAYA Ş., Mildanoglu M. M., COŞKUN A., ERCAN UZUNDAL D., ŞAHİN T. K., et al.TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)
38. Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross-Sectional StudyŞAHİN T. K., Sahin E. A., Gungor H. N., GÜVEN D. C., BARIŞTA İ., AKIN S.CANCER MEDICINE, cilt.14, sa.7, 2025 (SCI-Expanded, Scopus)
39. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) StudyKalkan Z., Ebinç S., Arcagok M., BİLİCİ A., YILDIZ Ö., KILIÇKAP S., et al.MEDICINA-LITHUANIA, cilt.61, sa.4, 2025 (SCI-Expanded, Scopus)
40. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancerSahin T. K., Rizzo A., GÜVEN D. C., AKSOY S.CANCER TREATMENT REVIEWS, cilt.135, 2025 (SCI-Expanded, Scopus)
41. Sirolimus experience in adult patients with vascular malformationsAKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.Vascular, cilt.33, sa.2, ss.404-409, 2025 (SCI-Expanded, Scopus)
42. Clinical Characteristics and Management of Patients Admitted to the Supportive Care Clinic and Predisposing Factors of Unplanned Hospital Readmission: Single-Center ExperienceBAŞ O., Tokatli M., Guduk N., Erdogan D., Boyraz N. E., Cengelci C., et al.JOURNAL OF CLINICAL MEDICINE, cilt.14, sa.8, 2025 (SCI-Expanded, Scopus)
43. Serum Albumin-Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with CancerBAŞ O., Guduk N., Tokatli M., Guven D. C., ÖZER N., ŞENER Y. Z., et al.JOURNAL OF CLINICAL MEDICINE, cilt.14, sa.5, 2025 (SCI-Expanded, Scopus)
44. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic ScoreKUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.JOURNAL OF CLINICAL MEDICINE, cilt.14, sa.6, 2025 (SCI-Expanded, Scopus)
45. Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancerAKYILDIZ A., Ismayilov R., Abdurrahimli N., Ormanci A., GÜVEN D. C., TUNCEL M., et al.JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.55, sa.2, ss.100-105, 2025 (SCI-Expanded, Scopus)
46. Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitorsBAŞ O., Tokatli M., Savkliyildiz M., Yazarkan Y., Guduk N., Kilinc C., et al.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.25, sa.4, ss.405-409, 2025 (SCI-Expanded, Scopus)
47. Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitorsŞAHİN T. K., AKSOY S., GÜVEN D. C.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.25, sa.5, ss.471-484, 2025 (SCI-Expanded, Scopus)
48. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaYildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.JOURNAL OF CHEMOTHERAPY, cilt.37, sa.6, ss.551-562, 2025 (SCI-Expanded, Scopus)
49. The association between HALP score and survival in patients treated with immune checkpoint inhibitorsŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.25, sa.1, ss.81-89, 2025 (SCI-Expanded, Scopus)
50. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitorsŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, cilt.25, sa.4, ss.129-137, 2025 (SCI-Expanded, Scopus)
51. The perspectives and knowledge of patients with cancer on mpox and mpox vaccination: a cross-sectional studyŞAHİN T. K., KAYGUSUZ Y., Icli M. C., AKSOY S., GÜVEN D. C.CURRENT MEDICAL RESEARCH AND OPINION, cilt.41, sa.1, ss.83-91, 2025 (SCI-Expanded, Scopus)
52. Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysisVitale E., Rizzo A., Maistrello L., GÜVEN D. C., Massafra R., Mollica V., et al.SCIENTIFIC REPORTS, cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)
53. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studyKahraman S., Hizal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., et al.BMC CANCER, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
54. Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based ModelComes M. C., Fanizzi A., Bove S., Boldrini L., Latorre A., GÜVEN D. C., et al.CANCER MEDICINE, cilt.13, sa.24, 2024 (SCI-Expanded, Scopus)
55. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancerYILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.BMC CANCER, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
56. Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysisSahin T. K., Guven D. C.CLINICAL NUTRITION ESPEN, cilt.63, ss.829-836, 2024 (ESCI, Scopus)
57. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus)
58. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumabYILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.BIOMOLECULES AND BIOMEDICINE, cilt.24, sa.4, ss.998-1003, 2024 (SCI-Expanded, Scopus)
59. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancerYILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.MEDICINE, cilt.103, sa.30, 2024 (SCI-Expanded, Scopus)
60. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitorsKAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.SUPPORTIVE CARE IN CANCER, cilt.32, sa.7, 2024 (SCI-Expanded, Scopus)

All 177 on AVESİS →

1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapyGÜVEN D. C., Incesu F. G. G., Yildirim H. C., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, cilt.33, (Özet Bildiri)
3. outcomes of patients with resected pancreatic ductal adenocarcinomaceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.9th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri)
4. Clinical features and prognosis of patients with liposarcoma: Single-center experience.Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)
5. MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?BİLGİN E., GÜVEN D. C., Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C., FIRLATAN B., et al.
6. Metastatic Choroidal Melanoma: Single Center ExperienceAKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al.
7. Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom AnaliziGÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., et al.
8. Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorektal patients and healty controls. Abst ID:”e15117”GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., et al.
9. Evaluation of cancer risk in patients with periodontal diseases.GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., et al.
10. Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis AnaliziGÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.
11. SEVERE PERIODONTITIS IS ASSOCIATED WITH INCREASED CANCER RISKDİZDAR Ö., HAYRAN K. M., GÜVEN D. C., Yılmaz T. B., Taheri S., AKMAN A. C., et al.

1. PATOFİZYOLOJİNİN TEMELLERİDURUSU TANRIÖVER M., SARI A., EŞME M., KOÇ YILDIRIM S., YILDIRIM M. Ş., BÖLEK E. Ç., et al.PALME YAYINCILIK, 2017